← Lung Cancer

CEUS- versus US- and CT-guided Biopsy for Subpleural Lung Lesions: A Prospective, Multicenter Randomized Controlled Trial.

IPBronch Review

🎯 Background & Rationale

  • Subpleural lesions: Subpleural lung lesions can be visualized clearly by conventional ultrasound, making it the guideline-recommended percutaneous approach.
  • CT utilization: Despite ultrasound advantages, computed tomography remains widely used due to its ability to visualize deep central lesions and comprehensive chest views.
  • Clinical gap: While contrast-enhanced ultrasound improves vascular visualization and lesion differentiation, no large randomized controlled trial has systematically compared contrast-enhanced ultrasound against conventional ultrasound and computed tomography for subpleural lung lesion biopsy.

👥 Study Design & Population

  • Study type: This was a prospective, multicenter, open-label, analyst-blinded, parallel-group randomized controlled trial conducted across four major Chinese tertiary hospitals.
  • Participants: A total of 2485 patients scheduled for percutaneous lung needle biopsy of subpleural lung lesions were randomized to ultrasound (n = 828), contrast-enhanced ultrasound (n = 829), or computed tomography (n = 828) groups.
  • Baseline parity: Baseline demographics, lesion size, anatomic location, and malignant proportions (overall approximately 74% to 77%) were well-balanced across all three study arms.

📈 Methodology & Rigor

  • Randomization scheme: Patients were randomized in a 1:1:1 ratio via a centralized, web-based, computer-generated system ensuring robust allocation concealment.
  • Blinding measures: Operator allocation was revealed only immediately before the procedure; data collectors, statistical analysts, pathologists, and microbiologists remained blinded.
  • Statistical rigor: Primary analyses were performed in the intention-to-treat population using multiple imputation for missing data, supplemented by per-protocol analyses and worst-case sensitivity models.

🔬 Key Findings [or Planned Endpoints]

  • Diagnostic yield: Contrast-enhanced ultrasound achieved the highest diagnostic yield at 88.8% (736/829), outperforming computed tomography at 78.9% (653/828) and ultrasound at 76.0% (629/828) (chi-square = 49.046, P < 0.001).
  • Diagnostic sensitivity: Overall disease sensitivity was highest with contrast-enhanced ultrasound at 86.1% (714/829), versus 74.3% (615/828) for computed tomography and 68.7% (569/828) for ultrasound (chi-square = 72.623, P < 0.001).
  • Malignant subtypes: Contrast-enhanced ultrasound yielded superior sensitivity for malignant subtypes like adenocarcinoma and squamous cell carcinoma (91.8% vs 83.2% vs 75.2%, chi-square = 62.259, P < 0.001).
  • Benign disorders: Contrast-enhanced ultrasound achieved superior sensitivity for specific benign disorders like tuberculosis and abscesses (69.9% vs 46.8% vs 47.1%, chi-square = 29.712, P < 0.001).
  • Complication rates: The overall procedural complication rate was lowest in the contrast-enhanced ultrasound group at 4.6% (38/828), followed by ultrasound at 7.5% (60/802) and computed tomography at 15.8% (127/805) (chi-square = 65.322, P < 0.001).

⚖️ Critical Appraisal

  • Internal validity: The trial benefits from a very large, well-powered sample size, multicenter design, robust allocation concealment, and blinded outcome assessment.
  • Generalizability: Results are robust across multiple centers in China, though operator dependence in ultrasound and needle selection introduces minor institutional variability.
  • Minor limitations: Simple randomization without site stratification was utilized, and secondary outcomes like core needle biopsy versus fine needle aspiration utilization varied by group.

💡 The Clinical Bottom Line

Contrast-enhanced ultrasound-guided percutaneous lung needle biopsy significantly improves diagnostic yield, malignant and benign disease-specific sensitivity, and procedural safety compared to conventional ultrasound and computed tomography guidance. For subpleural lung lesions, contrast-enhanced ultrasound should be adopted as an optimal standard technique to maximize tissue adequacy while minimizing complications.


BACKGROUND: Ultrasound (US)-guided percutaneous lung needle biopsy (PLNB), the guideline-recommended approach for subpleural lung lesion (SLL) diagnosis, requires comparison with CT-guided biopsy based on high-level evidence clinical studies. RESEARCH QUESTION: Is US-guided PLNB superior to CT-guided biopsy in diagnostic performance and safety, and does CEUS provide further advantages? STUDY DESIGN AND METHODS: Participants undergoing PLNB for SLLs between June 2020 and November 2023 were randomized to US-, CEUS- and CT-guided biopsies. The dual primary outcomes were diagnostic yield and disease-specific diagnostic sensitivity. Diagnostic yield was defined according to the strict ATS/ACCP definition as the proportion of biopsies yielding clinically actionable diagnoses, while sensitivity referred to the proportion of patients with a confirmed disease correctly identified by biopsy. Four secondary outcomes included complication rate, CNB/FNA utilization, puncture number, and puncture time, with the overall complication rate adopted as the key safety indicator. RESULTS: A total of 2485 participants were randomized into the US (n=828), CEUS (n=829) and CT (n=828) groups. The CEUS-guided biopsy achieved the highest diagnostic yield (CEUS: 88.8%[736/829] vs. CT: 78.9%[653/828] vs. US: 76.0%[629/828], χ=49.046, P <0.001) , as well as the highest diagnostic sensitivity (CEUS: 86.1%[714/829] vs. CT: 74.3%[615/828] vs. US: 68.7%[569/828], χ=72.623, P <0.001). For disease-specific analysis, CEUS yielded superior diagnostic sensitivity for malignant subtypes (CEUS: 91.8%[563/613] vs. CT: 83.2%[520/625] vs. US: 75.2%[479/637], χ=62.259, P <0.001) and specific benign disorders (CEUS: 69.9%[151/216] vs. CT: 46.8%[95/203] vs. US: 47.1%[90/191], χ=29.712, P <0.001). Furthermore, the CEUS group exhibited the lowest overall complication rate (CEUS: 4.6%[38/828] vs. US: 7.5%[60/802] vs. CT: 15.8%[127/805], χ=65.322, P <0.001). INTERPRETATION: For SLL biopsy, CEUS-guided PLNB outperforms US- and CT-guided approaches in both diagnostic performance and procedural safety. CEUS guidance notably improves disease-specific diagnostic sensitivity for malignant subtypes and specific benign pulmonary disorders, serving as an optimal technique for clinical percutaneous lung biopsy. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry; No.: ChiCTR2100045374; URL: www.chictr.org.cn.
Read the full paper ↗

Keep reading

N opens the next one